Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

​Author(s): Parker C.C.; Dearnaley D.P.; James N.D.; Brawley C.D.; Ritchie A.W.S.; Gilson C.; Langley R.E.; Millman R.; Amos C.L.; Parmar M.K.B.; Sydes M.R.; Clarke N.W.; Hoyle A.P.; Ali A.; Tran A.T.H.; Attard G.; Chowdhury S.; Cross W.; Gillessen S.; Jones R.J.; Russell J.M.; Malik Z.I.; Eswar C.; Mason M.D.; Matheson D.; Thalmann G.N.; Alonzi R.; Bahl A.; Birtle A.; Din O.; Douis H.; Gale J.; Gannon M.R.; Jonnada S.; Khaksar S.; Lester J.F.; O'Sullivan J.M.; Parikh O.A.; Pedley I.D.; Pudney D.M.; Sheehan D.J.; Srihari N.N.
Source: The Lancet; Dec 2018; vol. 392 (no. 10162); p. 2353-2366
Publication Date: Dec 2018
Publication Type(s): Article
PubMedID: 30355464
Abstract:Background: Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low metastatic burden. We aimed to compare standard of care for metastatic prostate cancer, with and without radiotherapy. Method(s): We did a randomised controlled phase 3 trial at 117 hospitals in Switzerland and the UK. Eligible patients had newly diagnosed metastatic prostate cancer.